Opening ceremony of joint ward
Before this academic conference, the opening ceremony of the joint ward of hematology department of Peking University People’s Hospital was held. Professor Huang Xiaojun, director of the National Clinical Medical Research Center for Hematology Diseases and director of Peking University Institute of Hematology, President Jin Dapeng, vice president of Chinese Medical Association and former director and secretary of Beijing Municipal Health Bureau, President Yan Xiaowen of Chinese Pharmacists Association, President Ji Jiafu of Peking University Cancer Hospital and President Lu Peihua of Lu Daopei Hospital attended the unveiling ceremony and delivered speeches successively. Huang Xiaoyan, Executive Dean of Beijing Lu Daopei Hematology Hospital, presided over the unveiling ceremony.
I. Guest speeches
1. Professor Huang Xiaojun: Standardized treatment is the trend of tumor treatment.
First of all, as the president of this conference, I would like to welcome and thank all of you for coming to the conference. Cell therapy based on CAR-T is the third treatment for malignant hematological tumors, and it is also the most active field at present. Another trend of tumor treatment is standardized treatment.
At the same time, we are here to hold the unveiling ceremony of Peking University Hematology Joint Ward, which means paying attention to it. The joint ward of hematology department of Peking University People’s Hospital is located in Lu Daopei Hospital, which indicates that Lu Daopei Medical Group, a very dynamic private hospital, has joined the national innovation system. The joint ward will serve as a standardized platform to promote technology development and help establish a national blood disease innovation system.
2. President Jin Dapeng: Develop through inheritance and inherit through development.
I am very happy to attend the unveiling ceremony of the joint ward of hematology department of Peking University People’s Hospital and the Lu Daopei Medical Cell Therapy Conference in Beijing. The 21st century is the century of biological science. Precision medicine, cancer treatment, stem cells and regenerative medicine are the hot topics at present. Research-oriented hospitals are an important part of the development practice and exploration of medical services in China, and the establishment of this joint ward has the same significance. The application of T cells has blossomed, and T cell therapy has not only achieved a "healing" effect in the field of blood tumor treatment, but also made new breakthroughs in the field of solid tumors. Immunotherapy, especially CAR-T cell therapy, illuminates the road of medical science and represents the direction of cancer treatment.
Academician Lu Daopei is a pioneer, leader and pioneer of hematological diseases in China. In the field of hematological diseases, we are in the same strain. I hope that you will follow the footsteps of academicians to develop your career, develop in inheritance and inherit in development.
"The frost is full of heart blood, and it is sprinkled on Qianfeng Qiuyedan." I would like to pay high tribute to the experts and scholars who have devoted themselves to the cause of hematological diseases in China, and extend my eternal blessing to Academician Lu Daopei. Congratulations on the successful opening of the cell therapy conference and the establishment of the joint ward of hematology department of Peking University People’s Hospital. I hope Lu Daopei Medical Group will take this opportunity to forge ahead for the healthy development of research hospitals in China.
3. President Yan Xiaowen: Work together and seek common development.
It is a great honor to attend such a sophisticated academic conference in the field of hematological oncology. China Pharmacists Association is the home of licensed pharmacists and clinical pharmacists, and is committed to providing better and more effective clinical pharmacist services for experts and scholars. In the near future, we will also carry out in-depth cooperation with Lu Daopei Hospital, Peking University Institute of Hematology, Peking University Cancer Hospital, etc. to jointly promote the progress of hematological tumor treatment in China.
4. Dean Ji Jiafu: Clinical research is an important measure of the academic value of hospitals.
Academician Lu Daopei is the most respected and proud teacher of our northern medical people. The establishment of the joint ward of hematology department of Peking University People’s Hospital provides an exploration direction for the social medical mode and the reform and development of public hospitals. As a research hospital, the development of clinical research is an important measure of the academic value of social medical services and public hospitals. On behalf of Peking University Cancer Hospital and China Anti-Cancer Association, I would like to congratulate the establishment of the joint ward. Peking University Cancer Hospital sincerely hopes to provide high-quality medical services for patients together with Lu Daopei Hospital.
5. Dean Lu Peihua: Join forces to open a new chapter in career.
On April 16th, experts gathered in weddings, Shunyi Campus of Lu Daopei Hospital. We held an important academic conference here and witnessed an important historical moment. Thanks to Director Huang Xiaojun, President Jin Dapeng of Chinese Medical Association, President Yan Xiaowen of Chinese Pharmacists Association, and Dean Ji Jiafu of Peking University Cancer Hospital for attending the event and opening the joint ward of hematology department of Peking University People’s Hospital!
On behalf of Academician Lu Daopei and Lu Daopei Medical Group, I would like to extend my warm congratulations on the establishment of the joint ward! In the spring of the new era, our two medical institutions will join forces again, which will surely open up a new world and achieve a new cause!
The First Lu Daopei Medical Cell Therapy Conference
In the form of online and offline, this conference invited 18 speakers, 37 presenters and discussion guests to share wonderful reports on the latest research progress and hot issues in the field of cell therapy, and at the same time conducted in-depth exchanges and discussions on the problems in clinical practice in this field.
The conference was co-chaired by Professor Huang Xiaojun, Director of Peking University Institute of Hematology, Professor of the First Affiliated Hospital of Suzhou University, Professor of the Institute of Hematology of China Academy of Medical Sciences, Professor of Harbin Institute of Hematology and Professor Zhu Jun of Peking University Cancer Hospital, and was chaired by Professor Lu Peihua, Executive Dean of Lu Daopei Hospital, Professor Liu Kaiyan, Deputy Director of Peking University Institute of Hematology and Executive Vice President of Beijing Lu Daopei Institute of Hematology. And invited authoritative experts in the field of CAR-T cell therapy and many famous scholars in the field of hematology at home and abroad to participate in the conference, and published wonderful academic reports, with big coffee gathering, full of dry goods and brilliant. Medical workers from medical institutions all over the country, doctors from hospitals of Lu Daopei Medical Group and laboratory doctors attended the meeting online and offline.
I. Speech by the President of the General Assembly
1. Speech by Professor Wu Depei from the First Affiliated Hospital of Soochow University:
As the chairman of Hematology Branch of Chinese Medical Association, I am very happy to attend the Lu Daopei Medical Cell Therapy Conference. Cell therapy is in the ascendant, and it is a hot treatment field at present, which shows excellent curative effect in clinic. Lu Daopei Medical Group, founded by Academician Lu Daopei, is at the forefront of the whole country and even the whole world in terms of cell therapy and laboratory tests, and has set a benchmark for the development of blood industry in China. I wish Lu Daopei Medical Group better and better. I hope that you will carry forward Academician Lu Daopei’s rigorous spirit of scholarship and highly responsible attitude towards patients, and make our due contribution to the cause of hematological diseases.
2. Speech by Professor Lin Yang from Beijing anzhen hospital affiliated to Capital Medical University:
On behalf of the Management Committee of Clinical Trial Drugs of Chinese Pharmacists Association, I would like to congratulate the grand convening of this conference and wish it a complete success.
3. Speech by Professor Liu Kaiyan, Deputy Director of Peking University Institute of Hematology and Executive Vice President of Beijing Lu Daopei Institute of Hematology:
First of all, warm congratulations on the establishment of the joint ward of Peking University People’s Hospital and Beijing Lu Daopei Institute of Hematology! At the same time, experts and scholars from all over the country are welcome to attend the Lu Daopei Medical Cell Therapy Conference. Cell therapy, especially CAR-T therapy, is playing an increasingly important role in the treatment of hematological malignancies. Since the CAR-T clinical trial was carried out in Lu Daopei Medical Group, more than 1,000 patients have been enrolled. At the same time, under the leadership of Dean Lu Peihua, the achievements in CAR-T field have a very leading position in China and even in the world. This cell therapy conference has built a platform for showing the progress of CAR-T therapy in China and communicating with colleagues at home and abroad. I wish the conference a complete success.
4. Speech by Professor Ding Sheng of Tsinghua University College of Pharmacy:
In the past many years, Lu Daopei Medical Group has been focusing on the diagnosis, treatment and scientific research transformation of blood system diseases, and enjoys a high reputation in the blood industry at home and abroad. On behalf of Tsinghua University Pharmaceutical College, I would like to congratulate the successful convening of this conference. Tsinghua Pharmaceutical College is committed to the research and development and application of cutting-edge technologies related to medicine, and promotes transformation research through cooperation with Lu Daopei Hospital and other medical institutions. I look forward to further cooperation and exchanges with Lu Daopei Hospital in the future.
5. Speech by Dean Lu Peihua:
Thank you again. We are very honored to get together with all your old and new friends online and offline. Thank you for passing on the classics and sending treasures through the platform of Lu Daopei Medical Cell Therapy Conference. Thank you for your support and trust from brother units, cell therapy research and development companies and patients. I wish you a career in by going up one flight of stairs.
6. Speech by Professor Ma Jun from Harbin Institute of Hematology and Oncology:
It is a great honor to attend this conference. Lu Daopei Medical Group has made great achievements in cell therapy, especially CAR-T therapy, and saved many patients with relapsed and refractory leukemia/lymphoma. I wish the conference a complete success!
7. Speech by Professor Zhu Jun from Peking University Cancer Hospital:
Since its establishment 20 years ago, Lu Daopei Hospital has made great progress in medical quality and patients’ reputation, which has been recognized by peers at home and abroad, and has played a demonstration and leading role in the national private blood cancer hospitals. He has made outstanding practice in cell therapy, especially CAR-T cell therapy, accumulated valuable experience and contributed to the development of blood industry in China. I look forward to further cooperation and exchange with Lu Daopei Hospital in the future, and wish the meeting a complete success!
Professor Jiang Min, Secretary-General of the conference and Director of Hematology Department of Beijing Lu Daopei Hospital, presided over the conference.
We gathered in the conference hall of Lu Daopei Blood Hospital to discuss the new harvest, new focus and new direction in the field of cell therapy deeply, comprehensively and enthusiastically, and explore the future of cell therapy. Thank you for the active participation of the hosts, speakers and discussion guests, because your participation has made the conference lineup strong, elite and colorful.
According to the agenda of the conference, the speakers brought wonderful academic reports one after another:
Second, the morning show
Professor Wang Luhua from MD Anderson Cancer Center shared "Novel Therapies to Overcome Car T Resistance".
Professor Song Yuqin of Peking University Cancer Hospital was the host, and had a discussion with guests Professor Jin Chenghao of Jiangxi Provincial People’s Hospital and Professor xuanwu hospital Su Li of Capital Medical University.
Professor Li Jianqiang of Hebei Senlang Biotechnology Co., Ltd. shared "the bottleneck and breakthrough direction of CAR-T cell therapy for tumor".
Wang Jianmin, Dean of Shanghai Daopei Hematology Hospital, presided over the meeting, and had discussions with Professor Liu Rong, a children’s hospital affiliated to Capital Institute of Pediatrics, and Professor Yang Tonghua, the First People’s Hospital of Yunnan Province.
Professor Yang Luhan of Hangzhou Qihan Biotechnology Co., Ltd. shared "the development of CAR-NK for treating tumors".
Professor Liu Qifa, director of the Institute of Hematology of Southern Medical University, presided over the meeting, and had a discussion with the guests, Professor Zhao Xiangyu from the Institute of Hematology of Peking University and Professor Zhang Weijing from the School of Oncology of Capital Medical University.
Professor Wang Jianxiang from Institute of Hematology, China Academy of Medical Sciences shared "the progress of CAR-T in China".
Professor Jiang Min served as the host and had a discussion with the guests Professor Jia Zhilin from the First Affiliated Hospital of Dalian Medical University and Professor Wei Xudong from Henan Cancer Hospital.
Professor Lu Peihua from Lu Daopei Hospital shared "CAR-T for Refractory/Recurrent Lymphoma".
Professor Huang He, Dean of the First Affiliated Hospital of Zhejiang University School of Medicine, presided over the meeting, and had a discussion with Professor Sun Yuqian from Peking University Institute of Hematology and Professor Wang Xiaopei from Peking University Cancer Hospital.
3. Afternoon performance
Professor Xu from Institute of Hematology, Xuzhou Medical University shared "CAR-T in the Treatment of Refractory and Recurrent B-cell Lymphoblastic Leukemia".
Professor Shi Yuankai from Cancer Hospital of China Academy of Medical Sciences presided over the meeting, and discussed with the guests Professor Zhang Xuejun from the Second Hospital of Hebei Medical University and Professor Huang Ning from the First Affiliated Hospital of Shandong First Medical University.
Professor Han Weidong from the First Medical Center of PLA General Hospital shared "Prevention and control of CRS in CAR-T cell therapy".
Professor Zhang Mingzhi, the First Affiliated Hospital of Zhengzhou University, presided over the meeting, and discussed with the guests Professor Jing Hongmei from Peking University Third Hospital and Professor Li Zhenling from China-Japan Friendship Hospital.
Professor tongji hospital Zhou Jianfeng, affiliated to Tongji Medical College, Huazhong University of Science and Technology, shared the "treatment system of relapsed and refractory multiple myeloma BCMA CAR-T".
Professor Zhang Leping from Peking University People’s Hospital was the host, and had a discussion with the guests Professor Liu Chuanfang from Qilu Hospital of Shandong University and Professor Zhao Mingfeng from Tianjin Medical University.
Professor Lin Xin of Tsinghua University Medical College shared "Research and Development and Clinical Application of Anti-CMV TCR-T Cells".
Professor Liao Xinsheng, an American hematology/oncology expert, presided over the meeting, and had discussions with distinguished guests Professor Dong Yujun from the First Hospital of Peking University and Professor Wang Quanshun from the Beijing Society of Hematology of Integrated Traditional Chinese and Western Medicine.
Professor Fu Cheng of the First Affiliated Hospital of Suzhou University shared "CAR-T in the treatment of myeloma, suitable for people to choose".
Professor Ren Jinhai, the Second Hospital of Hebei Medical University, presided over the meeting and had a discussion with the guests, Professor Beijing Chaoyang Hospital affiliated to Capital Medical University and Professor Zhuang Junling from Peking Union Medical College Hospital.
Director Zhang Xian of Hematology Department of Lu Daopei Hospital shared the experience of CAR-T treatment of Burkitte lymphoma.
Professor Zhou Xiaoge, Department of Pathology and Laboratory Medicine, Lu Daopei Hospital, Beijing/Department of Pathology, Beijing Friendship Hospital, presided over the meeting, and had a discussion with Professor Ma Liang Ming, guest of Shanxi Academy of Medical Sciences, and Professor Sarah, deputy director of the Department of Pathology and Laboratory Medicine and director of the flow cell room (vice president level) of Lu Daopei Medical Group.
Yang Junfang, Director of Hematology Department of Lu Daopei Hospital, shared "CAR-T Typical Case Sharing".
Professor Zhang Bolong of Lu Daopei Hospital presided over the meeting, and had a discussion with the guests, Director Lu Fanyong and Director Zhang Zhanqiang of Lu Daopei Hospital.
IV. Parallel Forum: Innovation and Transformation
Professor Wang Wenya of Tsinghua University served as the moderator of this forum.
Professor Chang Zhijie from Tsinghua University Medical College shared the "Application Research of Mesenchymal Stem Cells in Inflammation-related Diseases".
Professor Liao Xuebin from Tsinghua University College of Pharmacy shared "T cell failure and CAR-T cell therapy research".
Professor Zhang Jianmin of Peking Union Medical College shared the research and application of tumor immunotherapy based on γδT cells.
Professor Zhang Shuyi of Tsinghua University Pharmaceutical University shared "Intelligent Cell Design Driven by Synthetic Biology".
Professor Du Juanjuan from Tsinghua University College of Pharmacy shared the design and application of bispecific antibody drug conjugate.
Professor Pu Yiyi from Shanghai Than Shwe Biomedical Technology Co., Ltd. shared the "Overview of production quality management system in the process of cell therapy research and development".
Professor Wang Wenya from Tsinghua University shared the "Current Situation and Analysis of Cell Therapy Supervision Policy".
The conference has a strong academic atmosphere. Through the wonderful reports and sharing of experts and in-depth discussion on each topic, the online and offline participants can see the comprehensive and profound contents from the specific cases of cell therapy to the direction to be broken in the future and the thinking of the whole cell therapy industry. The academic reports are rich in content and typical cases are detailed, which truly realizes the sharing of resources and wisdom. With the completion of the conference schedule, the first Lu Daopei Medical Cell Therapy Conference came to an end. Dean Lu Peihua concluded that the online audience of the conference reached more than 20,000, and the video number audience was more than 4,000. The success of the conference is inseparable from the wonderful academic sharing of experts. I would like to express my heartfelt thanks to all the speakers and guests who presided over the discussion!
It is believed that the experts, scholars and clinicians attending the meeting, while learning from the successful experience of other experts, will have a deeper thinking on how to better apply cell therapy as a powerful weapon in clinical treatment. Let’s look forward to meeting again next year!